766539-34-8 Usage
Uses
Used in Pharmaceutical Industry:
BMA is used as a research compound for investigating the role of opioid receptors in the central nervous system. Its high affinity and selectivity for opioid receptors make it a valuable tool for understanding the mechanisms of opioid action and developing new drugs for pain management and addiction treatment.
Used in Drug Development:
BMA is used as a lead compound in the development of new opioid receptor ligands. Its structural similarity to naloxone, an opioid receptor antagonist, provides a foundation for designing and optimizing novel therapeutic agents with improved pharmacological properties and potential therapeutic uses.
Further research is needed to fully understand the pharmacological properties and potential therapeutic uses of BMA, including its efficacy, safety, and optimal dosing regimens. As a promising candidate for opioid receptor ligands, BMA holds the potential to contribute to the advancement of pain management and addiction treatment strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 766539-34-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,6,6,5,3 and 9 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 766539-34:
(8*7)+(7*6)+(6*6)+(5*5)+(4*3)+(3*9)+(2*3)+(1*4)=208
208 % 10 = 8
So 766539-34-8 is a valid CAS Registry Number.
766539-34-8Relevant academic research and scientific papers
A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
-
, (2012/10/08)
The present invention relates to a novel compound, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) comprising the same. The invention provides a compound, which has excellent activity and solubility and is more efficiently formulated and delivered, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 comprising the same.
